ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis

Acta Neurologica Scandinavica

Volumn 120, Issue 6, 2009, Pages 439-441

  Portaccio, E ^a   Zipoli, V ^a   Goretti, B ^a   Hakiki, B ^a   Nacmias, B ^a   Siracusa, G ^a   Sorbi, S ^a   Amato, M P ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Apolipoprotein E; Benign; Disability; Multiple sclerosis

Indexed keywords

APOLIPOPROTEIN E4;

ADULT; ALLELE; ARTICLE; CLINICAL ASSESSMENT; COGNITION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS;

ADULT; AGE OF ONSET; ALLELES; APOLIPOPROTEIN E4; CHI-SQUARE DISTRIBUTION; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 72849129081     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2009.01278.x     Document Type: Article

References (13)

1. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004 3 : 104 10.
2. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994 17 : 525 30.
3. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994 264 : 850 2.
4. Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993 90 : 1977 81.
5. Burwick RM, Ramsay PP, Haines JL et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers. Neurology 2006 66 : 1373 83.
6. Amato MP, Portaccio E, Stromillo ML et al. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology 2008 71 : 632 8.
7. Amato MP, Zipoli V, Goretti B et al. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol 2006 253 : 1054 9.
8. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 13 : 227 31.
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33 : 1444 52.
10. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 46 : 907 11.
11. Sorbi S, Nacmias B, Forleo P et al. ApoE allele frequencies in Italian sporadic and familial Alzheimer's disease. Neurosci Lett 1994 177 : 100 2.
12. Perini P, Tagliaferri C, Belloni M, Biasi G, Gallo P. The HLA-DR13 haplotype is associated with "benign" multiple sclerosis in northeast Italy. Neurology 2001 57 : 158 9.
13. Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol 2007 20 : 269 74.